“Global Allergic Rhinitis Drugs market set to grow to $14.3bn by 2022” says new Visiongain report

28 August 2018
Pharma

Visiongain has launched a new pharma report Global Allergic Rhinitis Drugs Market : Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.

There is a high and rapidly increasing unmet clinical need in allergic rhinitis. The prevalence of allergic rhinitis is increasing, driven by factors such as climate change, industrialisation, and changes in our exposure to potential allergens in early life. The pattern of increasing prevalence has been observed worldwide. In addition, climate change could lead to seasonal allergic rhinitis symptoms being present for a much greater proportion of the year, due to grasses and trees producing pollen earlier and for longer periods.

The lead analyst of the report commented "Immunotherapy for allergic rhinitis is expected to significantly increase its share of the overall allergic rhinitis drugs market over the forecast period. The launch of sublingual immunotherapy tablets in the US and expansion in Asia-Pacific markets is expected to drive high growth in this segment of the allergic rhinitis drugs market.

Immunotherapy has advantages over intranasal drugs in being a therapy that may lead to long-term prevention of symptoms; the closest thing to a ‘cure’ in allergic rhinitis. The pipeline for immunotherapy is particularly strong. There have also been developments in sublingual immunotherapy (SLIT), which will expand the use of immunotherapy."

Leading companies featured in the report include ALK-Abello, GSK, Johnson & Johnson, Kyowo Hako Kirin, Merck & Co, Sanofi, Stallergenes Greer, UCB.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever